ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection

Antiviral Therapy

Volumn 18, Issue 3, 2013, Pages 329-336

  Hochreiter, Jill ^a   Lapham, Jill ^a   Wong Staal, Flossie ^b   McKelvy, Jeffrey ^b   Sulkowski, Mark ^c   Glesby, Marshall J ^d   Johnson, Victoria A ^e   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b iTherX Pharmaceuticals Inc   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ITX 5061; ITX 8524; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENCY; ELECTROSPRAY MASS SPECTROMETRY; HEPATITIS C; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

CHROMATOGRAPHY, REVERSE-PHASE; HEPATITIS C; HUMANS; MASS SPECTROMETRY; PHENYLENEDIAMINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 84878088143     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2354     Document Type: Article

References (11)

1. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000; 17:1551-1557. (Pubitemid 32217566)
2. Food and Drug Administration. Guidance for industry on bioanalytical method validation; availability. Federal register, Vol. 66, no. 100, p. 28526. (Updated 23 May 2001. Accessed 4 July 2010.) Available from http://www.gpo.gov/ fdsys/pkg/FR-2001-05-23/pdf/01-12908.pdf
3. Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit 2006; 28:367-374. (Pubitemid 44314924)
4. Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004; 48:824-831. (Pubitemid 38280331)
5. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003; 75:3019-3030. (Pubitemid 36830428)
6. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 2007; 24:1962-1973. (Pubitemid 47389236)
7. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24:357-387. (Pubitemid 36724375)
8. Catanese MT, Ansuini H, Graziani R, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010; 84:34-43.
9. Dreux M, Dao Thi VL, Fresquet J, et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog 2009; 5:e1000310.
10. Syder AJ, Lee H, Zeisel MB, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54:48-55.
11. Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV entry for development of therapeutics. Viruses 2010; 2:1718-1733.